Allegra Authorized Generic Scripts Could Reach 40% By Year-End, Sanofi Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva describes the launch of its generic fexofenadine as one of the firm’s “most successful.”
You may also be interested in...
UCB’s Next Allergy Partner Is Sanofi-Aventis
Xyzal, pending in the U.S. for allergic rhinitis treatment, could be a replacement for Allegra.
UCB’s Next Allergy Partner Is Sanofi-Aventis
Xyzal, pending in the U.S. for allergic rhinitis treatment, could be a replacement for Allegra.
Teva/Barr Get The Green Light To Continue Marketing Generic Allegra
A New Jersey federal judge denied Sanofi-Aventis' request for a preliminary injunction to stop Teva/Barr from marketing generic Allegra.